Little Green Pharma has shifted its laboratory testing to the in-house lab of the Therapeutic Goods Administration (TGA) following the contentious publication of a TGA report identifying products which failed a potency audit.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

The WA-based firm was one of four suppliers named in the audit whose products were found to have breached TGO93 requirements. The others were Althea, Spectrum Therapeutics and Bedrocan.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...